Lenacapavir Sodium (2 brand names, 2 dosage forms, 2 routes)
Available dosage forms: SOLUTION, TABLET.
Routes of administration: SUBCUTANEOUS, ORAL.
Brand Names
- SUNLENCA
- YEZTUGO
Related Health Topics
Indications and Usage
SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.
Contraindications
Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1)].
Adverse Reactions
The following adverse reactions are discussed in other sections of the labeling: Immune Reconstitution Syndrome [see Warnings and Precautions (5.1)] Injection Site Reactions [see Warnings and Precautions (5.3)].
Mechanism of Action
SUNLENCA is an HIV-1 antiretroviral agent [see Microbiology (12.4)].
Overdosage
No data are available on overdose of SUNLENCA in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with SUNLENCA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. As lenacapavir is highly bound to plasma proteins, it is unlikely to be significantly removed by dialysis.